16,063 Novo Nordisk A/S $NVO Shares Bought by Hantz Financial Services Inc.
by Doug Wharley · The Cerbat GemHantz Financial Services Inc. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 13.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 133,369 shares of the company’s stock after purchasing an additional 16,063 shares during the quarter. Hantz Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $5,056,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Arrowstreet Capital Limited Partnership bought a new position in shares of Novo Nordisk A/S during the 1st quarter valued at $287,660,000. State Street Corp boosted its holdings in Novo Nordisk A/S by 0.6% in the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock worth $284,565,000 after purchasing an additional 32,641 shares in the last quarter. Royal Bank of Canada boosted its holdings in Novo Nordisk A/S by 3.2% in the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after purchasing an additional 141,376 shares in the last quarter. Envestnet Asset Management Inc. boosted its holdings in Novo Nordisk A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after purchasing an additional 71,684 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Novo Nordisk A/S by 6.7% during the first quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after buying an additional 213,443 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Price Performance
Shares of Novo Nordisk A/S stock opened at $41.60 on Tuesday. The firm has a fifty day simple moving average of $39.99 and a 200-day simple moving average of $43.24. The company has a current ratio of 0.84, a quick ratio of 0.64 and a debt-to-equity ratio of 0.54. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The stock has a market capitalization of $185.73 billion, a price-to-earnings ratio of 10.45, a PEG ratio of 1.40 and a beta of 0.70.
Key Stories Impacting Novo Nordisk A/S
Investors following NVO have been watching these stories:
- Positive Sentiment: The European Commission approved Frehemgo, Novo’s treatment for hemophilia A, adding a new approved product to its portfolio. NVO’s Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
- Positive Sentiment: Additional CagriSema analyses showed substantial weight loss among patients who responded early, including average losses of up to 25% in that subgroup. The results bolster the drug’s prospects, though they are not the overall trial outcome. Novo Nordisk reports additional CagriSema weight-loss findings
- Neutral Sentiment: Novo presented research suggesting amylin-based medicines may help preserve bone health during weight loss. The findings support ongoing research but are not evidence of an approved treatment benefit. Novo presents preclinical and human data on bone health
Analysts Set New Price Targets
Several equities analysts have weighed in on NVO shares. Cfra lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 target price on the stock. in a report on Tuesday, September 22nd. Jefferies Financial Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. UBS Group reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Five research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $59.44.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.
Recommended Stories
- Five stocks we like better than Novo Nordisk A/S
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).